Search
for
Sort by
Research 361–390 of 1000+
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib
- Deuruxolitinib for Alopecia Areata.
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
- Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- The Economic Burden of Alopecia Areata: Evidence from a Survey in Norway and Sweden
- Psychophysiological Mechanisms of Stress Impact on Hair Loss Processes
- Jak inhibitors in the treatment of alopecia areata - a literature review
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
- DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
- P100: Efficacy of current treatments under study in patients with alopecia areata
- JAK Inhibitors for Treatment of Alopecia Areata
- Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
- Modern Management Approaches for Alopecia Areata
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
- Rethinking the classification of alopecia areata
- Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Response to “Reply to effectiveness of dutasteride in a large series of patients with FFA in real clinical practice”
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- Alopecia universalis. Partial response to tofacitinib
- 1313 Fzd2 controls multiple aspects of epidermal development through distinct signaling mechanisms